AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03256357 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo observation training
Description: Placebo observation training consists of 15 sessions of 1 hour. Children perform the same actions as the AOT training after watching computer games without biological movements.
Study NCT03344146 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Medication intake reminders
Description: Acoustic and visual alarm at predefined DOAC-intake timepoints.
Study NCT03344146 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pillbox use and counselling
Description: All patients will be counselled based on their previous electronically recorded adherence data and will be given a multicompartment pillbox für daily use
Study NCT05485233 — intervention group
Intervention type: DEVICE
Intervention: REDSCAR App
Description: Patients will be discharged after surgery at the time it is considered by the responsible physician. Prior to discharge, patients taking part in the study will follow the same protocol as any other patient treated in our institution. Written consent will be signed after complete explanation of the study protocol by the researcher at this moment. The patient will download the RedScar© application and the researcher will explain how it works and how to answer all the questions about the wound (redness, pain).~At day 3th and 10th after surgery, each patient will upload an image of the surgical wound via RedScar© aplication using their own smartphone device. RedScar© aplication will evaluate the risk of complications of the surgical wound and will assign patients to 2 different groups: potential complications requiring new consultation or satisfactory evolution and discharge.
Study NCT01664507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional dose epinephrine
Description: conventional dose epinephrine : 0.5mg/kg + 0.9% normal saline
Study NCT01664507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose epinephrine
Description: low dose epineprhine : 0.1mg/kg + 0.9% normal saline
Study NCT01884545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: Telephonic health coaching sessions with a trained certified health coach for a period of 6 months (total of 10 biweekly calls).
Study NCT01884545 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic risk counseling
Description: In addition to the SRA subjects will receive genetic risk counseling at the risk counseling visit with a clinic provider. Genetic test results for CHD (rs10757274) and T2D (rs7903146, rs1801282, rs5219) risk variants will be incorporated into the risk profile reviewed with subjects.
Study NCT01884545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard risk assessment
Description: Standard risk assessment for coronary heart disease (CHD) and type 2 diabetes (T2D). Standard risk factors are reviewed by a provider at a risk counseling visit with the subject.
Study NCT01884545 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard risk assessment
Description: Standard risk assessment for coronary heart disease (CHD) and type 2 diabetes (T2D). Standard risk factors are reviewed by a provider at a risk counseling visit with the subject.
Study NCT04513171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-shape pegylated somatropin
Description: Y-shape pegylated somatropin 100μg/kg, subcutaneous injection, Once weekly.
Study NCT04513171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-shape pegylated somatropin
Description: Y-shape pegylated somatropin 120μg/kg, subcutaneous injection, Once weekly.
Study NCT04513171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-shape pegylated somatropin
Description: Y-shape pegylated somatropin 140μg/kg, subcutaneous injection, Once weekly.
Study NCT04513171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norditropin®
Description: Norditropin 245μg/kg/week, subcutaneous injection, Once daily.
Study NCT04513171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norditropin
Description: Norditropin 245μg/kg/week, subcutaneous injection, Once daily.
Study NCT02542592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
Study NCT02542592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Sodium Chloride
Description: Placebo
Study NCT04329572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Tablets
Description: All patients included in the study will receive AZT 500 mg per day for 5 days.
Study NCT02497846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEOSYAL® PureSense Redensity [I]/MicronJet®
Description: According the instruction of use, 3 injections of TEOSYAL® PureSense Redensity \[I\]will be performed all the 3 weeks. The used needle will be the MicronJet® microneedles for product injection. And the last visit (of control) will be performed 3 weeks after the last injection.
Study NCT02294851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986168
Study NCT02294851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BMS-986168 Placebo
Study NCT00847626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
Study NCT00847626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
Study NCT00847626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
Study NCT00847626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
Study NCT00847626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
Study NCT00847626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
Study NCT00847626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone
Description: Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
Study NCT00847626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone
Description: Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
Study NCT00847626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
Study NCT00847626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
Study NCT00847626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
Study NCT05213546 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise training
Description: bicycle ergometer exercise training
Study NCT03334253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: Daily 0.01% atropine eyedrops
Study NCT03334253 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Eyedrops
Description: Daily placebo eyedrops
Study NCT00333749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Drinking or rinsing the mouth 2-3 times for 1 day
Study NCT00333749 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pasturlized cow milk
Description: Drinking or rinsing the mouth 2-3 times for one day.
Study NCT00121667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin + Metformin
Description: Tablets, Oral, 2.5 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)
Study NCT00121667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin + Metformin
Description: Tablets, Oral, 5 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)
Study NCT00121667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin + Metformin
Description: Tablets, Oral, 10 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)
Study NCT00121667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Metformin
Description: Tablets, Oral, 0 mg, Once daily (24 weeks ST, 42 months LT)
Study NCT00121667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone
Description: Tablets, Oral, 15 - 45 mg (as needed for rescue)
Study NCT00121667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Tablets, Oral, 15 - 45 mg (as needed for rescue)
Study NCT01621243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel dosed on Day 1, Day 8, Day 15 of each 28-day cycle
Study NCT01621243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nab-paclitaxel
Description: nab-paclitaxel dosed on Day 1, Day 8, Day 15 of each 28-day cycle
Study NCT01621243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine will be dosed on Day 1, Day 8, Day 15 of each 28-day cycle
Study NCT01621243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gemcitabine
Description: gemcitabine will be dosed on Day 1, Day 8, Day 15 of each 28-day cycle
Study NCT01621243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be dosed daily
Study NCT01621243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Necuparanib
Description: Necuparanib will be dosed daily
Study NCT01953445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT01953445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study NCT00968526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK2340272A
Description: One or two intramuscular injections in the deltoid region of the non-dominant or the dominant arm.
Study NCT02935803 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Trans-vaginal Mesh operation
Description: Modified the transobturator TVM operation reported by Sergent et al. by inserting a stabilizing suture, which fixing the anterior edge of the mesh to the paraurethral tissues at the level of the mid-urethra with two non-resolvable anchoring stitches thereby promoting the proper elevation and closure of the urethra
Study NCT01948674 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized tasks
Description: The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.
Study NCT01948674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized tasks
Description: The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.
Study NCT01126034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention letter
Description: Physicians in the intervention group were mailed a written feedback letter regarding their patients who were prescribed questionable metoclopramide therapy. Non-intervention providers received no letter. The letter consisted of the following components:~1. The name and medical record # of the patients involved~2. Information regarding the metoclopramide prescription: dates, dosage, indication recorded, and the duration of therapy~3. A reminder of the adverse effect of long-term metoclopramide therapy~4. A recommendation to consider having the patient undergo a trial of metoclopramide discontinuation if appropriate, and documentation of a discussion of risk and benefits of metoclopramide therapy with patients~5. A request that the physician document the discontinuation trial in the electronic medical record
Study NCT04324905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1802
Description: Test drug
Study NCT04324905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1705
Description: Reference drug
Study NCT04079205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Device(exoRehab)
Description: rehabilitation program for patients after Anterior Cruciate Ligament Reconstruction using Wearable Device (exoRehab)
Study NCT04079205 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home rehabilitation program
Description: rehabilitation program for patients after Anterior Cruciate Ligament Reconstruction
Study NCT03188367 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gluten or placebo capsules
Description: Administration of gluten or placebo capsules
Study NCT03188367 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Gluten or placebo capsules
Description: Administration of gluten or placebo capsules
Study NCT02029963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (rTMS)
Description: A non-invasive method for brain stimulation
Study NCT02029963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: An individually-tailored maintenance plan as determined by a psychiatrist or primary care provider
Study NCT00915824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STOPP/START criteria
Description: Application of STOPP/START criteria to the patient's prescription and diagnostic information with subsequent written recommendation on pharmaceutical care to the patient's medical team
Study NCT04420429 — intervention group
Intervention type: PROCEDURE
Intervention: Descemet membrane endothelial keratoplasty (DMEK)
Description: All participants underwent DMEK surgery
Study NCT03142269 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 360°anterior capsule polishing
Description: 360°anterior capsule polishing was performed with double-ended capsule polisher
Study NCT03142269 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: 360°anterior capsule polishing
Description: 360°anterior capsule polishing was performed with double-ended capsule polisher
Study NCT04370015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with oral hydroxychloroquine 400 mg twice a day (four 200 mg tablets) on day 1 followed by 400mg (two 200 mg tablets) once a week for 11 weeks.
Study NCT04370015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: • Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with placebo twice a day (four tablets) on day 1 followed by 2 tablets once a week for 11weeks.
Study NCT03618004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.~The subjects of the experimental group made use of the restriction of blood flow, using a pressure cuff coupled in the most proximal region of the arm, 10 cm wide. The pressure was calculated based on the initial systolic pressure of the subjects.
Study NCT03618004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.~The subjects in the control group did not use pressure cuffs.
Study NCT03609268 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: microwave ablation (MWA)
Description: microwave ablation (MWA) for recurrent small liver cancer
Study NCT03609268 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy (SBRT)
Description: stereotactic body radiotherapy (SBRT) for recurrent small liver cancer
Study NCT00999739 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar and Pneumo23
Description: Two vaccines: participants will receive via intramuscular in deltoid one dose of conjugated heptavalent vaccine at day 0 (Prevenar, Wyeth-lederle)and one dose of 23valent polysaccharide vaccine (Pneumo23, AventisPasteur)at week4 One vaccine:participants will receive only one dose of 23valent polysaccharide vaccine at day 0.
Study NCT04483856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DermoRelizema cream
Description: Fingertip units (FTU) depending from the extent of the affected skin to treat, two times per day for 7 (±3) days prior RT until about 14 (±3) days post RT end. The product can be used for further 2 weeks (from V3 to V4) in case of need, according to the investigator's judgment
Study NCT04483856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexeryl
Description: FTUs depending on the extent of the affected skin to treat, two times per day. The treatment will be applied since 7 (±3) days prior to RT start and will continue until 14 days post RT end (98-112 applications in total).
Study NCT02489734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: extubation when end-tidal concentration of sevoflurane \< 0.5%
Study NCT02489734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: extubation when end-tidal concentration of sevoflurane >= 0.5%
Study NCT01834612 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CM1500
Description: blood volume monitor
Study NCT01834612 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CM1500
Description: blood volume monitor
Study NCT02610075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: All patients will receive intervention with AZD1775 orally. Patients will continue to receive treatment with AZD1775 until disease progression, intolerable toxicity, or discontinuation criteria are met.
Study NCT02478437 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiofrequency ablation (RFA)
Description: A conventional RFA electrode with a 10mm active tip will be used. RFA lesions will be performed for 90 seconds with the maximum electrode temperature raised to 80°C.
Study NCT02478437 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cooled Radiofrequency Ablation (CRFA)
Description: Following 18G C-RFA electrode positioning, 1cc of 2% lidocaine will be injected through the introducer needle for anesthesia during the ablation. The maximum electrode temperature is 60°C.
Study NCT00002838 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF)
Study NCT00002838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT00002838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Study NCT00002838 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Study NCT02697396 — intervention group
Intervention type: BEHAVIORAL
Intervention: Assessments
Description: All participants, after consent, will be asked to complete the study contact form and then complete a baseline assessment with the RSA. This baseline assessment will take approximately 5 minutes.
Study NCT02697396 — intervention group
Intervention type: OTHER
Intervention: Text Message Reminder
Description: Participants randomly assigned to the text messaging group will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after exposure to the social marketing campaign and time of consent.
Study NCT02697396 — intervention group
Intervention type: OTHER
Intervention: No Text Messaging
Description: Participants in this arm will receive no additional vaccination reminders.
Study NCT03516305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Staccato Alprazolam 1 mg
Description: alprazolam I mg administered via the Staccato hand-held inhaler device system.
Study NCT01914081 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Patients will receive one uncoated immediate-release caplets containing 500 mg resveratrol, twice daily for the 12 month intervention period